Stockscreener 앱 받기
38.62
0.03%
-0.01
시간 외 거래:
38.62
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Will Palvella Therapeutics Inc. stock split in the near futureReal Chart Play - Metal.it
What drives Palvella Therapeutics Inc. stock priceUnprecedented profit potential - Autocar Professional
Is Palvella Therapeutics Inc. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia
Why Palvella Therapeutics Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser
Palvella Therapeutics Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - Autocar Professional
Should I buy Palvella Therapeutics Inc. stock before earningsTriple-digit wealth increases - jammulinksnews.com
What analysts say about Palvella Therapeutics Inc. stockStrong return on investment - Autocar Professional
A Great Week for Institutional Investors Who Own 27% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - 富途牛牛
Palvella Therapeutics Inc (PVLA) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Truist Securities Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Truist Securities initiates Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
What makes Palvella Therapeutics Inc. stock price move sharplyLow Risk Consistent Winners - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin - Insider Monkey
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - simplywall.st
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
2,516 Shares in Palvella Therapeutics, Inc. (NASDAQ:PVLA) Purchased by Spire Wealth Management - Defense World
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 3000 Value Index - MarketScreener
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes - The Manila Times
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin - MyChesCo
Breakthrough Therapy: Phase 3 Trial Exceeds Target by 25% for First-Ever Microcystic LM Treatment - Stock Titan
Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener
Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph
Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN
Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World
Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks
0.97%
0.22%
자본화:
|
볼륨(24시간):